Alnylam uncovers genetic mutations in inhbe that protect against abdominal obesity

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today that the company and collaborators have identified mutations in the inhbe gene associated with protection against abdominal obesity and metabolic syndrome – a condition impacting more than 20 percent of adults worldwide. the discovery leveraged sequencing data from more than 360,000 individuals in uk biobank, and was published in the 13th issue of nature commun
ALNY Ratings Summary
ALNY Quant Ranking